Get the latest Sernova Corp (SVA) real. com uses cookies on this site. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Volume has increased on the last day along with the price, which is a. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Biopharmaceutical company Theratechnologies Inc. Stockhouse. By continuing to use our service, you agree to our use of cookies. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. The abstracts are now available at aacr. com. 68 to a day high of $1. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. is a speaker and consultant of Theratechnologies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 17% from a day low at $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share. By continuing to use our service, you agree to our use of cookies. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. Gary Littlejohn. S. " The 12-month stock price forecast is $18. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. We also use them to share usage information with our partners. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has decided to pause the enrollment of patients in its Phase 1 clinical. 4% annually. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. Stockhouse. Stockhouse. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 51 to 200 Employees. This news release constitutes a “designated news release” for the purposes of the. This suggests a possible upside of 2,471. 23 to a day high of $1. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. com uses cookies on this site. com uses cookies on this site. With the company starting 2023 with 8,725 employees, that’s an 11. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. 16%. This news release constitutes a “designated news release” for the purposes. Currency in USD Follow 2W 10W 9M 1. Cookies are used to offer you a better browsing experience and to analyze our traffic. 35 as of 10:41 a. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. We also use them to share usage information with our partners. (NASDAQ:THTX) Q2 2022 Earnings Conference Call July 14, 2021 8:30 AM ET. The firm offers its product under the brand name of. Read More. 29(+0. Theratechnologies. Stockhouse. (882) posted 3 minutes ago. Saint-Laurent, Canada. TORONTO, Sept. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies (THTX) Stock Price, News & Analysis $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, Jan. Theratechnologies develops and commercializes innovative therapies. 04) earnings per share (EPS) for the quarter. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (2021-01-19 | TSX:TH) Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option. . By continuing to use our service, you agree to our use of cookies. Vice President, Communications and Corporate Affairs. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Statut du système de négociation. ir@theratech. Agreement in principle on key amendments to loan. We also use them to share usage. Share your ideas and get valuable. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that all five of the U. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. communications@theratech. GUD | Complete Knight Therapeutics Inc. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. The company develops treatments for lipodystrophy . The business had revenue of $27. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xMain number: 514-336-7800. 14, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. VANCOUVER, British Columbia, Nov. Cookies are used to offer you a better browsing experience and to analyze our traffic. Company Type For Profit. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. S. Overview Stock Screener Earnings Calendar Sectors Nasdaq | THTX U. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". 4%. 5%. There are 102 news items for this page. Market Cap. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Focused on small-cap companies and sectors. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. By continuing to use our service, you agree to our use of cookies. Elif McDonald - Senior Director, Investor Relations. ET. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. THERATECHNOLOGIES INC. TH | September 5, 2023. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters. T. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. FAQ – Utilisateurs de TMX Argent NOUVEAU. MONTREAL, Sept. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. -4. 1-514-336-7800. By continuing to use our service, you agree to our use of cookies. 25. Stockhouse. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. 4% from the stock's current price. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. 54% and a negative trailing twelve-month return on equity of 1,116. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. Cookies are used to offer you a better browsing experience and to analyze our traffic. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. 514-336-7800. sBLA for F8 formulation of tesamorelin submitted to FDA. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. It is the Company’s proprietary peptide linked to. S. Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. communications@theratech. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at . About SORT1+ Technology™ and TH1902. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. com uses cookies on this site. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. 17. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. We also use them to share usage information with our partners. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. We also use them to share usage. MONTREAL, Jan. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Unveiling Silvercorp's golden potential at the Ying Mining District. Apr 14, 2020, 8:30 a. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced public offering (the “Public. Stockhouse. MONTREAL, Aug. com. When this page refreshes you will be logged in with the new address. - Q3 2022 Consolidated. MONTREAL, June 29, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSX: TH) announced today that the Supreme Court of Canada has granted its appeal and dismissed 121851 Canada Inc. 81 million for the quarter. Stockhouse. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to. stock news by MarketWatch. . Cookies are used to offer you a better browsing experience and to analyze our traffic. com uses cookies on this site. Theratechnologies Inc. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 4. Cookies are used to offer you a better browsing experience and to analyze our traffic. com 10/16/2023. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. - 2023 Q3 positive adjusted EBITDA to be achieved. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. com uses cookies on this site. - Q3 2022 Consolidated Revenue Growth of 17% to $20. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. High expression of the sortilin (SORT1) receptor correlates with decreased survival in triple‐negative breast cancer (TNBC) patients. 2. Theratechnologies stated the primary endpoint measured a 90 per cent confidence interval of the IM injection to IV injection (0. NCU. 9 million as at August 31, 2023. Last Reviewed: February 24, 2023. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 2. This module allows you to check different measures of market premium (i. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. com uses cookies on this site. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced dosing of the first participant in Part 3 of its Phase 1 clinical trial of. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. stockhouse. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Headquartered in Montreal, Quebec (Canada), Theratechnologies commercializes two medicines in HIV and has research programs in HIV, NASH and Oncology. 2015 Peel, 11th Floor Montreal, Quebec H3A 1T8 THERA technologies MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE YEAR ENDED NOVEMBER 30, 2021 The following Management’s Discussion and Analysis, or MD&A, provides Management’s point of view on the financial position and results of operations. October 13, 2022 07:30 ET | Source: Theratechnologies. View real-time stock prices and stock quotes for a full financial overview. 33. B2Gold Declares Fourth Quarter 2023 Dividend. View real-time stock prices and stock quotes for a full financial overview. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high expression of. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. 9 million and US. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. Theratechnologies présente des données démontrant la surexpression de la sortiline (SORT1) dans plusieurs types de tumeurs au 34e symposium de l’EORTC-NCI-AACRVice President, Communications and Corporate Affairs. T. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. (“Theratechnologies”) with the Securities and Exchange Commission (the. Cookies are used to offer you a better browsing experience and to analyze our traffic. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 08 (+6. ET. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results. Theratechnologies reduces R&D head count to compensate for sales setback. TH | October 13, 2022 - Q3 2022 Consolidated. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. T. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Katana shareholders will. Track Theratechnologies Inc. Theratechnologies Stock Price, News and Company Updates. MONTREAL, Feb. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2020-10-22 | TSX:TH) Theratechnologies to Present at Upcoming Investor Conferences on October 29 and November 10, 2020. (TH. We also use them to share usage. 49) by $0. Stockhouse. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. European Headquarters. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Theratechnologies, Inc. com. Montréal, Québec, Canada . Phone Number 15143319691. The webinar will also address system-level barriers and present real-world. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. Senior Director, Investor Relations. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. It's a different kind of fat that may require a different type of treatment. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Cookies are used to offer you a better browsing experience and to. 23) diluted earnings per. US Headquarters. Investor Relations. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. TH | February 28, 2023. W. Further. By continuing to use our service, you agree to our use of cookies. Competitors: Unknown. 0. com. com uses cookies on this site. - October 10, 2023) - KO Gold Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Q4 2022 consolidated revenue growth of 14. Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) today announced the publication of a preclinical study demonstrating the in vitro and in vivo efficacy of TH1902, an investigational sortilin (SORT1)-targeted peptide-drug conjugate, in inhibiting ovarian cancer and triple-negative breast cancer (TNBC. THTX | Complete Theratechnologies Inc. European Headquarters. com. Cookies are used to offer you a better browsing experience and to analyze our traffic. Forecast to breakeven in 2024 Jul 15. T. . By continuing to use our. MONTREAL, Sept. 40 f102M H1. MONTREAL, Sept. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. Heures de négociation. RESSOURCES. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 00. Further. com. : Renegotiated Lease to Generate Substantial Annual Savings. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TH. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023 financial results on Thursday, November 9, 2023 prior to market opening. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. Theratechnologies inc. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. Selected news for Normal, Illinois and Cancer Therapy, which are filed under Locations / US Cities and Healthcare Topics, respectively. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 06 million, an increase of 14. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. MONTREAL, Sept. TH | Complete Theratechnologies Inc. Paul Levesque - President. lgibson. If you have HIV, it's important to know the difference. Following the release, Knight will hold a conference call and audio webcast. We currently market prescription products for people with HIV in the United States. Who is Theratechnologies. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. Theratechnologies has generated ($1. TH | May 19, 2023. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. (2021-11-23 | TSX:TH) Theratechnologies Announces Renewal of Shelf Prospectus and Registration Statement; At-The-Market Facility to be Extended. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. communications@theratech. , a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. MONTREAL, Jan. Denis Boucher. S. Microsoft (NDAQ:MSFT) will expand its presence in Quebec with new computing capacity and AI and. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. (TH. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected] uses cookies on this site. /NOT FOR DISTRIBUTION TO UNITED STATES OF AMERICA WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES OF AMERICA/. During the last trading day the stock fluctuated 12. 2% per year. We also use them to share usage. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 13, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 51 S1. com uses cookies on this site. However, it did not meet the equivalence limits of 0. Q3 2023 consolidated revenue of $20. Cenicriviroc (CVC) is a novel, orally administered, chemokine receptor type 2 and 5 antagonist that showed antifibrotic potential in preclinical and phase IIb studies of nonalcoholic steatohepatitis (NASH). 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. MONTREAL, Aug. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650 [email protected] Inc. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. About Theratechnologies.